| pegylated liposomal doxorubicin / Generic mfg. |
NCT00189410: Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours |
|
|
| Completed | 2 | 140 | Europe | Pegylated Liposomal Doxorubicin and Carboplatin | AGO Study Group, MedServ. GmbH, Wiesbaden, Essex Pharma GmbH | Cancer of the Ovary Treated as 2nd Line Therapy, Muellerian Mixed Tumours, Tumours of the Uterus, Cervical Cancers, Non-Epithelial Ovarian Tumours | 09/05 | 09/06 | | |
NCT00097019: A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed |
|
|
| Completed | 2 | 53 | NA | bevacizumab | Genentech, Inc. | Ovarian Cancer | 05/06 | 05/06 | | |
NCT00312650: Doxil and Gemcitabine in Recurrent Ovarian Cancer |
|
|
| Terminated | 2 | 24 | US | liposomal doxorubicin and gemcitabine | Women and Infants Hospital of Rhode Island, Ortho Biotech, Inc. | Ovarian Carcinoma | 05/06 | 05/06 | | |
NCT00216645: Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based Chemotherapy |
|
|
| Completed | 2 | 74 | Japan | doxorubicin hydrochloride | Janssen Pharmaceutical K.K. | Ovarian Neoplasms | | 11/06 | | |
NCT00780039: A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625) |
|
|
| Completed | 2 | 58 | NA | Pegylated Liposomal Doxorubicin, SCH 200746, Carboplatin | Merck Sharp & Dohme LLC, Princess Margaret Hospital, Canada | Ovarian Neoplasms | 09/07 | 09/07 | | |
NCT00426127: Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer |
|
|
| Terminated | 2 | 2 | US | Docetaxel, Taxotere, Liposomal Doxorubicin, caelyx, Enoxaparin, Lovenox | University of Iowa, Aventis Pharmaceuticals | Pancreatic Cancer | 01/09 | 08/09 | | |
| Completed | 2 | 10 | Europe | recombinant interleukin-21, rIL-21, NN028, caelyx (pegylated liposomal doxorubicin) | Novo Nordisk A/S | Cancer, Ovarian Cancer | 01/09 | 01/09 | | |
NCT00610792 / 2005-003962-40: Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens |
|
|
| Withdrawn | 2 | 91 | Europe | bortezomib, VELCADE, pegylated liposomal doxorubicin, CAELYX | Millennium Pharmaceuticals, Inc. | Ovarian Cancer | 09/09 | | | |
PRECEDENT, NCT00722592: Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) |
|
|
| Completed | 2 | 162 | US | Vintafolide, EC145, pegylated liposomal doxorubicin (PLD), Doxil®, Caelyx®, EC20, 99mTc-EC20 | Endocyte | Ovarian Cancer | 09/10 | 12/12 | | |
|
|
|
|
|
|
|
|
|
|
NCT00698451: A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers |
|
|
| Completed | 2 | 54 | US | doxorubicin HCL liposome; bevacizumab; carboplatin | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Centocor Ortho Biotech Services, L.L.C. | Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms | 10/10 | 10/10 | | |
|
NCT00945139: Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA) |
|
|
| Completed | 2 | 46 | US | Doxil, Doxorubicin, Avastin, Bevacizumab | New Mexico Cancer Care Alliance, Genentech, Inc., NYU Langone Health | Ovarian Cancer | 12/10 | 08/11 | | |
|
NCT00248248: DOXIL for Consolidation Therapy in Ovarian Cancer. |
|
|
| Completed | 2 | 45 | US | liposomal doxorubicin | Southeastern Gynecologic Oncology, Ortho Biotech, Inc. | Ovarian Neoplasm | 10/11 | 10/11 | | |
| Completed | 2 | 168 | US, Canada, Europe, RoW | ABT-888, ABT-888, veliparib, pegylated liposomal doxorubicin, doxil/caelyx, temozolomide, temozolomide, temodar/temodal | AbbVie (prior sponsor, Abbott) | Ovarian Cancer | 06/13 | 06/13 | | |
| Completed | 2 | 110 | Europe | Paclitaxel, Gemcitabine, Topotecan, Pegylated liposomal doxorubicin (PLD), BI 6727 | Boehringer Ingelheim | Ovarian Neoplasms | 06/14 | 06/14 | | |
NCT01991210 / 2012-005776-34: A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) |
|
|
| Terminated | 2 | 95 | US, Canada, Europe | DNIB0600A, RO5541081, PLD | Genentech, Inc. | Ovarian Cancer | 08/16 | 08/16 | | |
|
NCT00052065: TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer |
|
|
| Completed | 1/2 | 28 | US | TLK286 | Telik | Ovarian Neoplasms | 03/06 | 03/06 | | |
NCT00562185: Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer |
|
|
| Withdrawn | 1/2 | 0 | US | carboplatin, doxorubicin hydrochloride | University of Texas Southwestern Medical Center, Ortho Biotech Clinical Affairs, L.L.C. | Ovarian Cancer | 03/09 | 03/09 | | |
